Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

High-sensitivity Troponin (hs-Tn) for Cardiovascular Risk Prognostication: A Systematic Review and Meta-analysis

Author(s): Marios Sagris*, Alexios S. Antonopoulos, Andreas Angelopoulos, Paraskevi Papanikolaou, Spyridon Simantiris, Constantinos Vamvakaris, Alkmini Koumpoura, Maria Farmaki, Charalambos Antoniades, Constantinos Tsioufis and Dimitris Tousoulis

Volume 31, Issue 14, 2024

Published on: 19 May, 2023

Page: [1941 - 1953] Pages: 13

DOI: 10.2174/0929867330666230315152045

Price: $65

Abstract

Background: Chronic low-grade inflammation is involved in coronary atherosclerosis progression whereas recent research efforts suggest that preventative methods should be tailored to the “residual inflammatory risk”. As such, modalities for the early identification of the risk have to be investigated.

Methods: We performed a systematic review and meta-analysis according to the PRISMA guidelines. Any study that presented the prognostic value of high sensitivity troponin (hs-cTn) of vascular inflammation in stable patients without known cardiac heart disease was considered to be potentially eligible. The Medline (PubMed) database was searched up to April 22, 2021. The main endpoint was the difference in c-index (Δ[c-index]) with the use of hs-cTn for major adverse cardiovascular events (MACEs), cardiovascular and all-cause mortality. We calculated I2 to test heterogeneity.

Results: In total, 44 studies and 112,288 stable patients without known coronary heart disease were included in this meta-analysis. The mean follow-up duration of the whole cohort was 6.8 ± 1.1 years. 77,004 (68.5%) of the patients presented at low cardiovascular risk while 35,284 (31.5%) in high. The overall pooled estimate of Δ[c-index] for MACE was 1.4% (95%CI: 0.7-2.1, I2=0%) and for cardiovascular death 1.3% (95%CI: 0.3-2.3, I2=0%). Finally, the overall pooled estimate of Δ[c-index] for all-cause mortality was 3% (95%CI: 1.9-3.9, I2=86%), while high heterogeneity was observed between the studies.

Conclusion: The predictive usefulness of changes in hs-cTn measures in stable individuals with either high or low cardiovascular risk, demonstrates that assessing vascular inflammation in addition to clinical risk factors enhances risk prediction for cardiovascular events and allcause mortality. Further prospective studies are necessary to confirm these findings and assist clinical decision-making regarding the most optimal prevention strategy.

« Previous
[1]
Polonsky, T.S.; McClelland, R.L.; Jorgensen, N.W.; Bild, D.E.; Burke, G.L.; Guerci, A.D.; Greenland, P. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA, 2010, 303(16), 1610-1616.
[http://dx.doi.org/10.1001/jama.2010.461] [PMID: 20424251]
[2]
Khamis, R.Y.; Ammari, T.; Mikhail, G.W. Gender differences in coronary heart disease. Heart, 2016, 102(14), 1142-1149.
[http://dx.doi.org/10.1136/heartjnl-2014-306463] [PMID: 27126397]
[3]
Sagris, M.; Antonopoulos, A.S.; Theofilis, P.; Oikonomou, E.; Siasos, G.; Tsalamandris, S.; Antoniades, C.; Brilakis, E.S.; Kaski, J.C.; Tousoulis, D. Risk factors profile of young and older patients with myocardial infarction. Cardiovasc. Res., 2022, 118(10), 2281-2292.
[PMID: 34358302]
[4]
Sagris, M.; Theofilis, P.; Antonopoulos, A.S.; Tsioufis, C.; Oikonomou, E.; Antoniades, C.; Crea, F.; Kaski, J.C.; Tousoulis, D. Inflammatory mechanisms in COVID-19 and atherosclerosis: Current pharmaceutical perspectives. Int. J. Mol. Sci., 2021, 22(12), 6607.
[http://dx.doi.org/10.3390/ijms22126607] [PMID: 34205487]
[5]
Sagris, M.; Kokkinidis, D.G.; Lempesis, I.G.; Giannopoulos, S.; Rallidis, L.; Mena-Hurtado, C.; Bakoyiannis, C. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease. Rev. Cardiovasc. Med., 2020, 21(4), 565-575.
[http://dx.doi.org/10.31083/j.rcm.2020.04.202] [PMID: 33388001]
[6]
Antonopoulos, A.S.; Angelopoulos, A.; Papanikolaou, P.; Simantiris, S.; Oikonomou, E.K.; Vamvakaris, K.; Koumpoura, A.; Farmaki, M.; Trivella, M.; Vlachopoulos, C.; Tsioufis, K.; Antoniades, C.; Tousoulis, D. Biomarkers of vascular inflammation for cardiovascular risk prognostication: A meta-analysis. JACC Cardiovasc. Imaging, 2022, 15(3), 460-471.
[PMID: 34801448]
[7]
Antonopoulos, A.S.; Sanna, F.; Sabharwal, N.; Thomas, S.; Oikonomou, E.K.; Herdman, L.; Margaritis, M.; Shirodaria, C.; Kampoli, A.M.; Akoumianakis, I.; Petrou, M.; Sayeed, R.; Krasopoulos, G.; Psarros, C.; Ciccone, P.; Brophy, C.M.; Digby, J.; Kelion, A.; Uberoi, R.; Anthony, S.; Alexopoulos, N.; Tousoulis, D.; Achenbach, S.; Neubauer, S.; Channon, K.M.; Antoniades, C. Detecting human coronary inflammation by imaging perivascular fat. Sci. Transl. Med., 2017, 9(398), eaal2658.
[http://dx.doi.org/10.1126/scitranslmed.aal2658] [PMID: 28701474]
[8]
McEvoy, J.W.; Chen, Y.; Ndumele, C.E.; Solomon, S.D.; Nambi, V.; Ballantyne, C.M.; Blumenthal, R.S.; Coresh, J.; Selvin, E. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol., 2016, 1(5), 519-528.
[http://dx.doi.org/10.1001/jamacardio.2016.0765] [PMID: 27439107]
[9]
Takeda, S.; Yamashita, A.; Maeda, K.; Maéda, Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature, 2003, 424(6944), 35-41.
[http://dx.doi.org/10.1038/nature01780] [PMID: 12840750]
[10]
Ooi, D.S.; Isotalo, P.A.; Veinot, J.P. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin. Chem., 2000, 46(3), 338-344.
[http://dx.doi.org/10.1093/clinchem/46.3.338] [PMID: 10702520]
[11]
Mohammad, M.A.; Koul, S.; Smith, J.G.; Noc, M.; Lang, I.; Holzer, M.; Clemmensen, P.; Jensen, U.; Engstrøm, T.; Arheden, H.; James, S.; Lindahl, B.; Metzler, B.; Erlinge, D. Predictive value of high-sensitivity troponin T for systolic dysfunction and infarct size (six months) after st-elevation myocardial infarction. Am. J. Cardiol., 2018, 122(5), 735-743.
[http://dx.doi.org/10.1016/j.amjcard.2018.05.005] [PMID: 30049462]
[12]
Moons, K.G.M.; Altman, D.G.; Reitsma, J.B.; Ioannidis, J.P.A.; Macaskill, P.; Steyerberg, E.W.; Vickers, A.J.; Ransohoff, D.F.; Collins, G.S. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med., 2015, 162(1), W1-W73.
[http://dx.doi.org/10.7326/M14-0698] [PMID: 25560730]
[13]
DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials, 1986, 7(3), 177-188.
[http://dx.doi.org/10.1016/0197-2456(86)90046-2] [PMID: 3802833]
[14]
Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414), 557-560.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[15]
Kim, Y.; Park, H.; Lee, H.K.; Nam, H.S.; Lee, Y.W.; Lee, S.G.; Park, Y.; Lee, W.; Nam, M.H.; Song, S.H.; Chung, J.W.; Lee, J. Development of statistical software for the korean laboratory accreditation program using R language: LaboStats. Ann. Lab. Med., 2019, 39(6), 552-560.
[http://dx.doi.org/10.3343/alm.2019.39.6.552] [PMID: 31240883]
[16]
Hayden, J.A.; van der Windt, D.A.; Cartwright, J.L.; Côté, P.; Bombardier, C. Assessing bias in studies of prognostic factors. Ann. Intern. Med., 2013, 158(4), 280-286.
[http://dx.doi.org/10.7326/0003-4819-158-4-201302190-00009] [PMID: 23420236]
[17]
Hinneburg, I. ROBINS-1: A tool for asssessing risk of bias in non-randomised studies of interventions. Med. Monatsschr. Pharm., 2017, 40(4), 175-177.
[PMID: 29952172]
[18]
Al-Badri, A.; Tahhan, A.S.; Sabbak, N.; Alkhoder, A.; Liu, C.; Ko, Y.A.; Vaccarino, V.; Martini, A.; Sidoti, A.; Goodwin, C.; Ghazzal, B.; Beshiri, A.; Murtagh, G.; Mehta, P.K.; Quyyumi, A.A. Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. J. Am. Heart Assoc., 2020, 9(8), e015515.
[http://dx.doi.org/10.1161/JAHA.119.015515] [PMID: 32301366]
[19]
Biener, M.; Giannitsis, E.; Kuhner, M.; Zelniker, T.; Mueller-Hennessen, M.; Vafaie, M.; Trenk, D.; Neumann, F.J.; Hochholzer, W.; Katus, H.A. Prognostic value of high-sensitivity cardiac troponin T compared with risk scores in stable cardiovascular disease. Am. J. Med., 2017, 130(5), 572-582.
[http://dx.doi.org/10.1016/j.amjmed.2016.11.028] [PMID: 28011313]
[20]
Clemens, R.K.; Annema, W.; Baumann, F.; Roth-Zetzsche, S.; Seifert, B.; von Eckardstein, A.; Amann-Vesti, B.R. Cardiac biomarkers but not measures of vascular atherosclerosis predict mortality in patients with peripheral artery disease. Clin. Chim. Acta, 2019, 495, 215-220.
[http://dx.doi.org/10.1016/j.cca.2019.04.061] [PMID: 30981846]
[21]
deFilippi, C.R.; de Lemos, J.A.; Christenson, R.H.; Gottdiener, J.S.; Kop, W.J.; Zhan, M.; Seliger, S.L. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA, 2010, 304(22), 2494-2502.
[http://dx.doi.org/10.1001/jama.2010.1708] [PMID: 21078811]
[22]
Leistner, D.M.; Klotsche, J.; Pieper, L.; Stalla, G.K.; Lehnert, H.; Silber, S.; März, W.; Wittchen, H.U.; Zeiher, A.M.; Group, D.S. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin. Chem., 2012, 58(1), 200-208.
[http://dx.doi.org/10.1373/clinchem.2011.174292] [PMID: 22156668]
[23]
Lyngbakken, M.N.; Skranes, J.B.; de Lemos, J.A.; Nygård, S.; Dalen, H.; Hveem, K.; Røsjø, H.; Omland, T. Impact of smoking on circulating cardiac troponin I concentrations and cardiovascular events in the general population. Circulation, 2016, 134(24), 1962-1972.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023726] [PMID: 27815376]
[24]
Resl, M.; Clodi, M.; Vila, G.; Luger, A.; Neuhold, S.; Wurm, R.; Adlbrecht, C.; Strunk, G.; Fritzer-Szekeres, M.; Prager, R.; Pacher, R.; Hülsmann, M. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart, 2016, 102(24), 1963-1968.
[http://dx.doi.org/10.1136/heartjnl-2015-308949] [PMID: 27456261]
[25]
Saunders, J.T.; Nambi, V.; de Lemos, J.A.; Chambless, L.E.; Virani, S.S.; Boerwinkle, E.; Hoogeveen, R.C.; Liu, X.; Astor, B.C.; Mosley, T.H.; Folsom, A.R.; Heiss, G.; Coresh, J.; Ballantyne, C.M. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities study. Circulation, 2011, 123(13), 1367-1376.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.005264] [PMID: 21422391]
[26]
Beatty, A.L.; Ku, I.A.; Christenson, R.H.; DeFilippi, C.R.; Schiller, N.B.; Whooley, M.A. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul study. JAMA Intern. Med., 2013, 173(9), 763-769.
[http://dx.doi.org/10.1001/jamainternmed.2013.116] [PMID: 23568589]
[27]
Biener, M.; Giannitsis, E.; Kuhner, M.; Zelniker, T.; Mueller-Hennessen, M.; Vafaie, M.; Stoyanov, K.M.; Neumann, F.J.; Katus, H.A.; Hochholzer, W.; Valina, C.M. Risk prediction in stable cardiovascular disease using a high-sensitivity cardiac troponin T single biomarker strategy compared to the ESC-SCORE. Open Heart, 2018, 5(1), e000710.
[http://dx.doi.org/10.1136/openhrt-2017-000710] [PMID: 29713483]
[28]
Biener, M.; Giannitsis, E.; Lamerz, J.; Mueller-Hennessen, M.; Vafaie, M.; Katus, H.A. Prognostic value of elevated high-sensitivity cardiac troponin T levels in a low risk outpatient population with cardiovascular disease. Eur. Heart J. Acute Cardiovasc. Care, 2016, 5(6), 409-418.
[http://dx.doi.org/10.1177/2048872615610869] [PMID: 26450785]
[29]
Eggers, K.M.; Kempf, T.; Larsson, A.; Lindahl, B.; Venge, P.; Wallentin, L.; Wollert, K.C.; Lind, L. Evaluation of temporal changes in cardiovascular biomarker concentrations improves risk prediction in an elderly population from the community. Clin. Chem., 2016, 62(3), 485-493.
[http://dx.doi.org/10.1373/clinchem.2015.246876] [PMID: 26769752]
[30]
Giannitsis, E.; Spanuth, E.; Horsch, A.; Kleber, M.E.; Koch, W.; Grammer, T.B.; Koenig, W.; März, W. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: Results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical Chemistry and Laboratory Medicine (CCLM), 2013, 51(10), 2019-2028.
[http://dx.doi.org/10.1515/cclm-2012-0786] [PMID: 24072576]
[31]
Hamaya, R.; Yonetsu, T.; Kanaji, Y.; Usui, E.; Hoshino, M.; Hada, M.; Kanno, Y.; Murai, T.; Lee, T.; Kakuta, T. Interrelationship in the prognostic efficacy of regional coronary flow reserve, fractional flow reserve, high-sensitivity cardiac troponin-I and NT-proBNP in patients with stable coronary artery disease. Heart Vessels, 2019, 34(3), 410-418.
[http://dx.doi.org/10.1007/s00380-018-1260-z] [PMID: 30229410]
[32]
Kavsak, P.A.; Xu, L.; Yusuf, S.; McQueen, M.J. High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. Clin. Chem., 2011, 57(8), 1146-1153.
[http://dx.doi.org/10.1373/clinchem.2011.164574] [PMID: 21700956]
[33]
Lupón, J.; de Antonio, M.; Galán, A.; Vila, J.; Zamora, E.; Urrutia, A.; Bayes-Genis, A. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs. conventional assessment. Mayo Clin. Proc., 2013, 88(3), 234-243.
[http://dx.doi.org/10.1016/j.mayocp.2012.09.016] [PMID: 23384388]
[34]
Tveit, S.H.; Myhre, P.L.; Hoff, N.J.S.; Le, T.M.; Seljeflot, I.; Røysland, R.; Høiseth, A.D.; Røsjø, H.; Omland, T. Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain; data from the Akershus cardiac Examination (ACE) 3 study. Clin. Biochem., 2020, 78, 10-17.
[http://dx.doi.org/10.1016/j.clinbiochem.2019.12.016] [PMID: 31899280]
[35]
Chen, T.; Hassan, H.C.; Qian, P.; Vu, M.; Makris, A. High-sensitivity troponin t and c-reactive protein have different prognostic values in hemo- and peritoneal dialysis populations: A cohort study. J. Am. Heart Assoc., 2018, 7(5), e007876.
[http://dx.doi.org/10.1161/JAHA.117.007876] [PMID: 29478023]
[36]
Desai, Y.B.; Mishra, R.K.; Fang, Q.; Whooley, M.A.; Schiller, N.B. Association of longitudinal change in high- sensitivity troponin with all-cause mortality in coronary artery disease: The heart and soul study. Cardiology, 2020, 145(2), 63-70.
[http://dx.doi.org/10.1159/000503954] [PMID: 31910405]
[37]
Hillis, G.S.; Welsh, P.; Chalmers, J.; Perkovic, V.; Chow, C.K.; Li, Q.; Jun, M.; Neal, B.; Zoungas, S.; Poulter, N.; Mancia, G.; Williams, B.; Sattar, N.; Woodward, M. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care, 2014, 37(1), 295-303.
[http://dx.doi.org/10.2337/dc13-1165] [PMID: 24089534]
[38]
Pareek, M.; Bhatt, D.L.; Vaduganathan, M.; Biering-Sørensen, T.; Qamar, A.; Diederichsen, A.C.P.; Møller, J.E.; Hindersson, P.; Leósdóttir, M.; Magnusson, M.; Nilsson, P.M.; Olsen, M.H. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur. J. Prev. Cardiol., 2017, 24(15), 1648-1659.
[http://dx.doi.org/10.1177/2047487317717065] [PMID: 28644092]
[39]
Tang, O.; Daya, N.; Matsushita, K.; Coresh, J.; Sharrett, A.R.; Hoogeveen, R.; Jia, X.; Windham, B.G.; Ballantyne, C.; Selvin, E. Performance of high-sensitivity cardiac troponin assays to reflect comorbidity burden and improve mortality risk stratification in older adults with diabetes. Diabetes Care, 2020, 43(6), 1200-1208.
[http://dx.doi.org/10.2337/dc19-2043] [PMID: 32161049]
[40]
Thorsteinsdottir, I.; Aspelund, T.; Gudmundsson, E.; Eiriksdottir, G.; Harris, T.B.; Launer, L.J.; Gudnason, V.; Venge, P. High-sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the AGES-reykjavik community-based cohort of older individuals. Clin. Chem., 2016, 62(4), 623-630.
[http://dx.doi.org/10.1373/clinchem.2015.250811] [PMID: 26936931]
[41]
Xiao, W.; Cao, R.; Liu, Y.; Wang, F.; Bai, Y.; Wu, H.; Ye, P. Association of high-sensitivity cardiac troponin T with mortality and cardiovascular events in a community-based prospective study in Beijing. BMJ Open, 2017, 7(6), e013431.
[http://dx.doi.org/10.1136/bmjopen-2016-013431] [PMID: 28652289]
[42]
Zeller, T.; Tunstall-Pedoe, H.; Saarela, O.; Ojeda, F.; Schnabel, R.B.; Tuovinen, T.; Woodward, M.; Struthers, A.; Hughes, M.; Kee, F.; Salomaa, V.; Kuulasmaa, K.; Blankenberg, S.; Investigators, M. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: The MORGAM Biomarker Project Scottish Cohort. Eur. Heart J., 2014, 35(5), 271-281.
[http://dx.doi.org/10.1093/eurheartj/eht406] [PMID: 24104876]
[43]
Galsgaard, J.; Persson, F.; Hansen, T.W.; Jorsal, A.; Tarnow, L.; Parving, H.H.; Rossing, P. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney Int., 2017, 92(5), 1242-1248.
[http://dx.doi.org/10.1016/j.kint.2017.04.018] [PMID: 28712855]
[44]
Gijsberts, C.M.; den Ruijter, H.M.; de Kleijn, D.P.V.; Huisman, A.; ten Berg, M.; de Groot, M.; van Wijk, R.H.A.; Asselbergs, F.W.; Voskuil, M.; Pasterkamp, G.; van Solinge, W.W.; Hoefer, I.E. Hematological parameters outperform plasma markers in predicting long-term mortality after coronary angiography. Angiology, 2018, 69(7), 600-608.
[http://dx.doi.org/10.1177/0003319717743679] [PMID: 29202601]
[45]
Gregg, L.P.; Adams-Huet, B.; Li, X.; Colbert, G.; Jain, N.; de Lemos, J.A.; Hedayati, S.S. Effect modification of chronic kidney disease on the association of circulating and imaging cardiac biomarkers with outcomes. J. Am. Heart Assoc., 2017, 6(7), e005235.
[http://dx.doi.org/10.1161/JAHA.116.005235] [PMID: 28679558]
[46]
Harada, Y.; Michel, J.; Koenig, W.; Rheude, T.; Colleran, R.; Giacoppo, D.; Kastrati, A.; Byrne, R.A. Prognostic value of cardiac troponin T and sex in patients undergoing elective percutaneous coronary intervention. J. Am. Heart Assoc., 2016, 5(12), e004464.
[http://dx.doi.org/10.1161/JAHA.116.004464] [PMID: 27895042]
[47]
Hasegawa, M.; Ishii, J.; Kitagawa, F.; Kanayama, K.; Takahashi, H.; Ozaki, Y.; Yuzawa, Y. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. Heart Vessels, 2013, 28(4), 473-479.
[http://dx.doi.org/10.1007/s00380-012-0273-2] [PMID: 22914904]
[48]
Keller, T.; Wanner, C.; Krane, V.; Kraus, D.; Genser, B.; Scharnagl, H.; März, W.; Drechsler, C. Prognostic value of high-sensitivity versus conventional cardiac troponin T assays among patients with type 2 diabetes mellitus undergoing maintenance hemodialysis. Am. J. Kidney Dis., 2018, 71(6), 822-830.
[http://dx.doi.org/10.1053/j.ajkd.2017.10.016] [PMID: 29310884]
[49]
Otaki, Y.; Takahashi, H.; Watanabe, T.; Yamaura, G.; Funayama, A.; Arimoto, T.; Shishido, T.; Miyamoto, T.; Kubota, I. Heart-type fatty acid binding protein and high-sensitivity troponin T are myocardial damage markers that could predict adverse clinical outcomes in patients with peripheral artery disease. BBA Clin., 2015, 4, 35-41.
[http://dx.doi.org/10.1016/j.bbacli.2015.06.003] [PMID: 26673681]
[50]
Samman Tahhan, A.; Sandesara, P.; Hayek, S.S.; Hammadah, M.; Alkhoder, A.; Kelli, H.M.; Topel, M.; O’Neal, W.T.; Ghasemzadeh, N.; Ko, Y.A.; Gafeer, M.M.; Abdelhadi, N.; Choudhary, F.; Patel, K.; Beshiri, A.; Murtagh, G.; Kim, J.; Wilson, P.; Shaw, L.; Vaccarino, V.; Epstein, S.E.; Sperling, L.; Quyyumi, A.A. High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes. J. Am. Heart Assoc., 2018, 7(5), e007914.
[http://dx.doi.org/10.1161/JAHA.117.007914] [PMID: 29467150]
[51]
Matsushita, K.; Sang, Y.; Ballew, S.H.; Astor, B.C.; Hoogeveen, R.C.; Solomon, S.D.; Ballantyne, C.M.; Woodward, M.; Coresh, J. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: The Atherosclerosis Risk in Communities study. Arterioscler. Thromb. Vasc. Biol., 2014, 34(8), 1770-1777.
[http://dx.doi.org/10.1161/ATVBAHA.114.303465] [PMID: 24876355]
[52]
McQueen, M.J.; Kavsak, P.A.; Xu, L.; Shestakovska, O.; Yusuf, S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin. Biochem., 2013, 46(1-2), 5-9.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.10.003] [PMID: 23063983]
[53]
Sigurdardottir, F.D.; Lyngbakken, M.N.; Holmen, O.L.; Dalen, H.; Hveem, K.; Røsjø, H.; Omland, T. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-trøndelag Health [HUNT] study). Am. J. Cardiol., 2018, 121(8), 949-955.
[http://dx.doi.org/10.1016/j.amjcard.2018.01.004] [PMID: 29496193]
[54]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 2009, 6(7), e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[55]
Samara, I.; Tsiara, S.; Papafaklis, M.I.; Pappas, K.; Kolios, G.; Vryzas, N.; Michalis, L.K.; Bairaktari, E.T.; Katsouras, C.S. Elderly patients with non-cardiac admissions and elevated high-sensitivity troponin: The prognostic value of renal function. World J. Cardiol., 2021, 13(10), 566-573.
[http://dx.doi.org/10.4330/wjc.v13.i10.566] [PMID: 34754401]
[56]
Kang, T.; Kim, G.S.; Byun, Y.S.; Kim, J.; Kim, S.; Chang, J.; Yoo, S.J. An algorithmic approach is superior to the 99th percentile upper reference limits of high sensitivity troponin as a threshold for safe discharge from the emergency department. Medicina, 2021, 57(10), 1083.
[http://dx.doi.org/10.3390/medicina57101083] [PMID: 34684124]
[57]
Diavati, S.; Sagris, M.; Terentes-Printzios, D.; Vlachopoulos, C. Anticoagulation treatment in venous thromboembolism: Options and optimal duration. Curr. Pharm. Des., 2022, 28(4), 296-305.
[http://dx.doi.org/10.2174/1381612827666211111150705] [PMID: 34766887]
[58]
Bonfanti, L.; Cervellin, G.; Calamai, S.; Lunian, M.; Aloe, R.; Lippi, G. Diagnostic significance of combining D-dimer with high-sensitivity cardiac troponin I for improving the diagnosis of venous thromboembolism in the emergency department. Acta Biomed., 2021, 92(5), e2021287.
[PMID: 34738598]
[59]
Theofilis, P.; Sagris, M.; Oikonomou, E.; Antonopoulos, A.S.; Siasos, G.; Tsioufis, C.; Tousoulis, D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines, 2021, 9(7), 781.
[http://dx.doi.org/10.3390/biomedicines9070781] [PMID: 34356845]
[60]
Theofilis, P.; Sagris, M.; Antonopoulos, A.S.; Oikonomou, E.; Tsioufis, C.; Tousoulis, D. Inflammatory mediators of platelet activation: Focus on atherosclerosis and COVID-19. Int. J. Mol. Sci., 2021, 22(20), 11170.
[http://dx.doi.org/10.3390/ijms222011170] [PMID: 34681830]
[61]
Oikonomou, E.; Tsaplaris, P.; Anastasiou, A.; Xenou, M.; Lampsas, S.; Siasos, G.; Pantelidis, P.; Theofilis, P.; Tsatsaragkou, A.; Katsarou, O.; Sagris, M.; Vavuranakis, M.A.; Vavuranakis, M.; Tousoulis, D. Interleukin-1 in coronary artery disease. Curr. Top. Med. Chem., 2022, 22(28), 2368-2389.
[http://dx.doi.org/10.2174/1568026623666221017144734] [PMID: 36263481]
[62]
Ridker, P.M.; Danielson, E.; Fonseca, F.A.H.; Genest, J.; Gotto, A.M., Jr; Kastelein, J.J.P.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J.; Group, J.S. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359(21), 2195-2207.
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[63]
Luo, W.; Guo, Y.; Huang, J.; Zhang, P. Do statins have a positive impact on patients with coronary microvascular dysfunction on long-term clinical outcome? A large retrospective cohort study. BioMed Res. Int., 2019, 2019, 1-8.
[http://dx.doi.org/10.1155/2019/4069097] [PMID: 31008104]
[64]
Bouabdallaoui, N.; Tardif, J.C.; Waters, D.D.; Pinto, F.J.; Maggioni, A.P.; Diaz, R.; Berry, C.; Koenig, W.; Lopez-Sendon, J.; Gamra, H.; Kiwan, G.S.; Blondeau, L.; Orfanos, A.; Ibrahim, R.; Grégoire, J.C.; Dubé, M.P.; Samuel, M.; Morel, O.; Lim, P.; Bertrand, O.F.; Kouz, S.; Guertin, M.C.; L’Allier, P.L.; Roubille, F. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur. Heart J., 2020, 41(42), 4092-4099.
[http://dx.doi.org/10.1093/eurheartj/ehaa659] [PMID: 32860034]
[65]
Zhu, Y.; Xian, X.; Wang, Z.; Bi, Y.; Chen, Q.; Han, X.; Tang, D.; Chen, R. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules, 2018, 8(3), 80.
[http://dx.doi.org/10.3390/biom8030080] [PMID: 30142970]
[66]
Monteagudo, L.A.; Boothby, A.; Gertner, E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol., 2020, 2(5), 276-282.
[http://dx.doi.org/10.1002/acr2.11135] [PMID: 32267081]
[67]
Bergström, U.; Jovinge, S.; Persson, J.; Jacobsson, L.T.H.; Turesson, C. Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr. Ther. Res. Clin. Exp., 2018, 89, 1-6.
[http://dx.doi.org/10.1016/j.curtheres.2018.07.001] [PMID: 30128057]
[68]
Chen, X.Y.; Yan, B.X.; Man, X.Y. TNFα inhibitor may be effective for severe COVID-19: Learning from toxic epidermal necrolysis. Ther. Adv. Respir. Dis., 2020, 14, 1753466620926800.
[http://dx.doi.org/10.1177/1753466620926800] [PMID: 32436460]
[69]
Wang, A.P.; Homme, J.L.; Qureshi, M.Y.; Sandoval, Y.; Jaffe, A.S. High-sensitivity troponin T testing for pediatric patients in the emergency department. Pediatr. Cardiol., 2022, 43(2), 350-359.
[PMID: 34787696]
[70]
Blankenberg, S.; Salomaa, V.; Makarova, N.; Ojeda, F.; Wild, P.; Lackner, K.J.; Jørgensen, T.; Thorand, B.; Peters, A.; Nauck, M.; Petersmann, A.; Vartiainen, E.; Veronesi, G.; Brambilla, P.; Costanzo, S.; Iacoviello, L.; Linden, G.; Yarnell, J.; Patterson, C.C.; Everett, B.M.; Ridker, P.M.; Kontto, J.; Schnabel, R.B.; Koenig, W.; Kee, F.; Zeller, T.; Kuulasmaa, K. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium. Eur. Heart J., 2016, 37(30), 2428-2437.
[http://dx.doi.org/10.1093/eurheartj/ehw172] [PMID: 27174290]
[71]
Januzzi, J.L., Jr; Butler, J.; Zannad, F.; Filippatos, G.; Ferreira, J.P.; Pocock, S.J.; Sattar, N.; Verma, S.; Vedin, O.; Iwata, T.; Brueckmann, M.; Packer, M.; Anker, S.D. Prognostic implications of N-terminal pro–B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-preserved. JACC Heart Fail., 2022, 10(7), 512-524.
[http://dx.doi.org/10.1016/j.jchf.2022.05.004] [PMID: 35670067]
[72]
Theofilis, P.; Sagris, M.; Oikonomou, E.; Antonopoulos, A.S.; Siasos, G.; Tsioufis, K.; Tousoulis, D. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. Int. Immunopharmacol., 2022, 111, 109080.
[http://dx.doi.org/10.1016/j.intimp.2022.109080] [PMID: 35908505]
[73]
Theofilis, P.; Sagris, M.; Oikonomou, E.; Antonopoulos, A.S.; Siasos, G.; Tsioufis, K.; Tousoulis, D. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res. Clin. Pract., 2022, 188, 109927.
[http://dx.doi.org/10.1016/j.diabres.2022.109927] [PMID: 35577035]
[74]
Myhre, P.L.; O’Meara, E.; Claggett, B.L.; de Denus, S.; Jarolim, P.; Anand, I.S.; Beldhuis, I.E.; Fleg, J.L.; Lewis, E.; Pitt, B.; Rouleau, J.L.; Solomon, S.D.; Pfeffer, M.A.; Desai, A.S. Cardiac troponin I and risk of cardiac events in patients with heart failure and preserved ejection fraction. Circ. Heart Fail., 2018, 11(11), e005312.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005312] [PMID: 30571192]
[75]
de Lemos, J.A.; Drazner, M.H.; Omland, T.; Ayers, C.R.; Khera, A.; Rohatgi, A.; Hashim, I.; Berry, J.D.; Das, S.R.; Morrow, D.A.; McGuire, D.K. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA, 2010, 304(22), 2503-2512.
[http://dx.doi.org/10.1001/jama.2010.1768] [PMID: 21139111]
[76]
Berger, A.; Simpson, A.; Bhagnani, T.; Leeper, N.J.; Murphy, B.; Nordstrom, B.; Ting, W.; Zhao, Q.; Berger, J.S. Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease. Am. J. Cardiol., 2019, 123(12), 1893-1899.
[http://dx.doi.org/10.1016/j.amjcard.2019.03.022] [PMID: 31014542]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy